Fever News and Research

RSS

Researchers test plants used in traditional African medicine against malaria

The malaria parasite has gradually developed resistance to the most commonly used medicines. To make matters worse, several mosquito species that host and transmit the parasite have become resistant to insecticides, making it difficult to eliminate them from populated areas.

8 Apr 2011

FluCide nanoviricide drug reduces overall leukocytes in lung tissue of influenza model

NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide drug candidates resulted in significant reduction in lung tissue presence of leukocytes, and in particular, that of eosinophils in a lethal influenza infection animal model.

8 Apr 2011

New publication on therapeutic hypothermia and temperature management

The successful use and evaluation of therapeutic hypothermia to improve survival and reduce the risk of neurological consequences following an out-of-hospital heart attack are explored in the premier issue of Therapeutic Hypothermia and Temperature Management, a new quarterly peer-reviewed journal published by Mary Ann Liebert, Inc.

8 Apr 2011

IBM discovers biodegradable nanoparticles that seek out and destroy drug-resistant bacteria

IBM's announcement of the first biodegradable nanoparticles that can seek out and destroy drug-resistant bacteria caps off a century of healthcare and life sciences innovation from IBM.

8 Apr 2011

AJG publishes new review on Inflammatory Bowel Disease management

The American College of Gastroenterology published a new evidence-based systematic review on the management of Inflammatory Bowel Disease as a supplement to The American Journal of Gastroenterology for April 2011, a special issue entirely dedicated to IBD.

8 Apr 2011

Shionogi launches CUVPOSA for pediatric chronic severe drooling

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.

7 Apr 2011

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

AstraZeneca today announced that the U.S. Food and Drug Administration approved the orphan drug vandetanib for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.

7 Apr 2011

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Seattle Genetics, Inc. today announced that data from a case series of Hodgkin lymphoma patients receiving brentuximab vedotin following allogeneic stem cell transplant were presented in an oral session at the European Group for Blood and Marrow Transplantation Annual Meeting in Paris, France.

7 Apr 2011

Hartwell honors UCSD scientists with Individual Biomedical Research Award

Three scientists at the University of California, San Diego School of Medicine are among this year's 12 winners of Hartwell Individual Biomedical Research Awards, honoring researchers whose work advances children's health.

7 Apr 2011

Post-infection treatment with NanoViricides FluCide reduces lung lesions caused by lethal influenza infection

NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide™ drug candidates resulted in dramatic reduction in the number of lung lesions that are caused by a lethal influenza virus infection. These findings were seen in the most recent H1N1 influenza animal study.

5 Apr 2011

South Sudan health workers face worst Kala-azar outbreak

South Sudan is facing the worst outbreak of Kala-azar in the past 10 years as health workers from Servant's Heart Relief race against the clock to stop the spread of the deadly disease.

5 Apr 2011

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved Viramune XR extended-release tablets, a one-pill, once-daily formulation of nevirapine for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

5 Apr 2011

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Idera Pharmaceuticals, Inc. announced today the presentation of data from a four-week Phase 1 clinical trial of IMO-2125 in combination with ribavirin in treatment-naïve patients chronically infected with hepatitis C virus genotype 1.

2 Apr 2011

Recent releases in Global Health

A Lancet Infectious Diseases editorial describes the growing public concerns over a global rise in antimicrobial resistance. "Bearing in mind that our objective is to contain antibiotic resistance rather than eradicate it, several policies could be adopted to help guarantee a future for antibiotics," the editorial states, adding, "We need reliable data to tackle antibiotic resistance.

2 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Vertex announces final results from Phase 3 REALIZE study against HCV

Vertex Pharmaceuticals Incorporated today announced final results from its pivotal Phase 3 REALIZE study that evaluated people with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon and ribavirin was unsuccessful either because they relapsed, had a partial response or had a null response.

1 Apr 2011

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Vertex Pharmaceuticals Incorporated today announced interim results from an ongoing Phase 2 study designed to assess the safety and tolerability of 12-week response-guided treatment regimens with its polymerase inhibitor, VX-222, and its protease inhibitor, telaprevir, in combination with pegylated-interferon and ribavirin in people with genotype 1 chronic hepatitis C who were new to treatment.

31 Mar 2011

New clinical practice guidelines developed for juvenile idiopathic arthritis

The American College of Rheumatology has developed new guidelines for starting and monitoring treatments for children with juvenile idiopathic arthritis. These are the first JIA guidelines endorsed by the ACR, with the goal of broad acceptance within the rheumatology community.

30 Mar 2011

Insect Shield Repellent Apparel can protect against tick bites

A pilot study shows clothes treated with long-lasting insect repellant appear to offer outdoor workers significant protection against tick bites.

30 Mar 2011

ACCF, AHA guidelines recognize Effient as Class I treatment option for patients with ACS-PCI

Oral antiplatelet therapy Effient has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients undergoing percutaneous coronary intervention fter experiencing heart-related chest pain at rest or non-ST segment elevation myocardial infarction.

30 Mar 2011

Fever News and Research

Researchers test plants used in traditional African medicine against malaria

FluCide nanoviricide drug reduces overall leukocytes in lung tissue of influenza model

New publication on therapeutic hypothermia and temperature management

IBM discovers biodegradable nanoparticles that seek out and destroy drug-resistant bacteria

AJG publishes new review on Inflammatory Bowel Disease management

Shionogi launches CUVPOSA for pediatric chronic severe drooling

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Hartwell honors UCSD scientists with Individual Biomedical Research Award

Post-infection treatment with NanoViricides FluCide reduces lung lesions caused by lethal influenza infection

South Sudan health workers face worst Kala-azar outbreak

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Recent releases in Global Health

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Vertex announces final results from Phase 3 REALIZE study against HCV

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

New clinical practice guidelines developed for juvenile idiopathic arthritis

Insect Shield Repellent Apparel can protect against tick bites

ACCF, AHA guidelines recognize Effient as Class I treatment option for patients with ACS-PCI

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News